Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang, Shulian Chen, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zepin Zhou, Fang Zhou, Rui Xi, Li Liu, Wei Yang, Xi Zhang, Qifa Liu, Erlie Jiang

Blood (2023) 142 (Supplement 1): 474.

https://doi.org/10.1182/blood-2023-184477

Published: 2023

Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2023-188489

Published: 2023

Journal Articles

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Junyuan Qi, Lin Song, Xudong Wei, Zhimin Zhai, Anyou Wang, Daozi Jiang, Yang Liang, Fei Li, Zhongxing Jiang, Xuejun Zhang, Qunyi Guo, Hongmei Jing, Yajing Xu, Xiangmin Tong, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2023-183088

Published: 2023

Journal Articles

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Blood (2023) 142 (Supplement 1): 4951.

https://doi.org/10.1182/blood-2023-184407

Published: 2023

Journal Articles

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

Biao Zheng, Rongrong Liu, Xinhua Zhang, Bin Fu, Yajing Xu, Jun Shi, Xiaoqin Feng, Li Wang, Chris Wang, Rongmei Liang, Lingzhi Tan, Fei Wang, Dali Li, Yuxuan Wu, Mingyao Liu, Yongrong Lai

Blood (2023) 142 (Supplement 1): 4995.

https://doi.org/10.1182/blood-2023-186031

Published: 2023

Journal Articles

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Shulian Chen, Xiaoyu Zhang, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Xi Rui, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Erlie Jiang

Blood (2022) 140 (Supplement 1): 10467–10468.

https://doi.org/10.1182/blood-2022-165140

Published: 2022

Journal Articles

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Blood (2022) 140 (Supplement 1): 4733–4734.

https://doi.org/10.1182/blood-2022-164640

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study

Can Liu, Ren Lin, Yu Wang, Fen Huang, MD, Zhiping Fan, MD, Shen Zhang, Yajing Xu, MD PhD, Ting Yang, Li Xuan, MD, Na Xu, Jieyu Ye, MD PhD, Jing Sun, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5693.

https://doi.org/10.1182/blood-2019-132106

Published: 2019

Journal Articles

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Weiran Lv, Hong Qu, Meiqing Wu, Zhiping Fan, MD, Fen Huang, Na Xu, PhD, Li Xuan, Ren Lin, Ke Zhao, Jing Sun, Yongrong Lai, MD, Yajing Xu, MD PhD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5736.

https://doi.org/10.1182/blood-2018-99-114043

Published: 2018

Journal Articles

Post-Transplantation Cyclophosphamide and Short-Term Methotrexate for Tolerance Induction in HLA-Haploidentical Transplantation for Severe Aplastic Anemia

Bin Fu, MD, Yajing Xu, MD PhD, Yan Chen, MD PhD, Fangping Chen, MD PhD

Blood (2017) 130 (Supplement 1): 3237.

https://doi.org/10.1182/blood.V130.Suppl_1.3237.3237

Published: 2017

Journal Articles

Two Doses of Antithymocyteglobulin As Graft-Versus-Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: A Multicenter Prospective Study

Ren Lin, Yu Wang, Fen Huang, Zhiping Fan, Shen Zhang, Ting Yang, Prof., MD, PhD, Yajing Xu, Xinquan Liang, Yu Ji, Na Xu, MD, Li Xuan, Jieyu Ye, PhD, Jing Sun, Xiaojun Huang, Qifa Liu, MD

Blood (2016) 128 (22): 4603.

https://doi.org/10.1182/blood.V128.22.4603.4603

Published: 2016

Journal Articles

Influence of Lower Dose Antithymocyteglobulin As Conditioning Regimen on Viral Infection after Haploidentical Allogeneic Stem Cell Transplantation

Ren Lin, Yu Wang, Fen Huang, Zhiping Fan, Shen Zhang, Ting Yang, Prof.,MD,PhD, Yajing Xu, Xinquan Liang, Yu Ji, Na Xu, MD, Li Xuan, Jieyu Ye, PhD, Jing Sun, Xiaojun Huang, Qifa Liu, MD

Blood (2016) 128 (22): 825.

https://doi.org/10.1182/blood.V128.22.825.825

Published: 2016

Journal Articles

Oral Administration of Ibrutinib Is Ineffective at Preventing Scleroderma in Chronic Gvhd in Two Preclinical Mouse Models

Yajing Xu, MD, Heather F Johnston, PhD, Stephen J. Forman, MD, Defu Zeng, MD

Blood (2014) 124 (21): 3818.

https://doi.org/10.1182/blood.V124.21.3818.3818

Published: 2014

NARROW

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Post-Transplantation Cyclophosphamide and Short-Term Methotrexate for Tolerance Induction in HLA-Haploidentical Transplantation for Severe Aplastic Anemia

Two Doses of Antithymocyteglobulin As Graft-Versus-Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: A Multicenter Prospective Study

Influence of Lower Dose Antithymocyteglobulin As Conditioning Regimen on Viral Infection after Haploidentical Allogeneic Stem Cell Transplantation

Oral Administration of Ibrutinib Is Ineffective at Preventing Scleroderma in Chronic Gvhd in Two Preclinical Mouse Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only